Physician profile
Jessie E Leeper
NPI 1770253692
$3,031.96
in general payments reported to CMS, 2019-2025
25 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.12 · 2022: $135 · 2023: $471 · 2024: $1,298 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,722.82 |
| Education | $155.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $460.17 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $427.40 | 2022-2025 | |
| Madrigal Pharmaceuticals | $378.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $261.06 | 2023-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.87 | 2022-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $131.89 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $123.45 | 2024 | Wegovy |
| Phathom Pharmaceuticals, INC. | $123.38 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $100.69 | 2024-2025 | Zenpep |
| Medtronic, INC. | $97.81 | 2023 | Interstim |
| Regeneron Healthcare Solutions, INC. | $91.20 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $87.45 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $72.65 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $64.89 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $58.74 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.09 | 2023-2025 | |
| Qol Medical, LLC | $51.31 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $50.92 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $35.44 | 2022-2023 | Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.51 | 2023-2024 | Cyltezo |
| Genzyme Corporation | $28.70 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $24.65 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $23.92 | 2023 | Rebyota |
| Fresenius Kabi USA, LLC | $20.94 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessie Leeper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.